Report Published: "United States Pharmaceuticals & Healthcare Report Q1 2015"

In the face of increasing product launches within highly-competitive therapeutic areas such as diabetes care in the US, payers are becoming ever more confident in leveraging their purchasing power over pharmaceutical companies. With few differentiating factors between competing products, pharmacy benefit managers and health insurers are in a position to secure better deals for themselves.

Headline Expenditure Projections

* Pharmaceuticals : USD347.2bn in 2013 to USD354.2bn in 2014; 2.0% growth. Forecast revised upwards from Q 4 14.
* Healthcare : USD2,918bn in 2013 to USD3,099bn in 2014; +6.2% growth. Forecast revised upwards from Q 4 14.

Risk/Reward Index (RR I ) : The US has a Pharmaceutical RRI score of 80.5 out of 100 for Q115. This is unchanged since last quarter but slightly higher than the 78.5 recorded in Q314 - which was due to an upgrade in BMI's forecasts for pharmaceutical expenditure over the next ten years. This development underlines the attractiveness of the market to all multinational drugmakers.

Full Report Details at
- http://www.fastmr.com/prod/938463_united_states_pharmaceuticals_healthcare_report.aspx?afid=301

Key Trends And Developments

November 2014

It emerged that US Senators Amy Klobuchar and John McCain will revive legislation that promotes imports of prescription medicines into the US from Canada. The bipartisan bill being revived and supported by Klobuchar and McCain will compel the pharmaceutical industry to reduce the prices of generic medicines in the country, according to the two senators.

The FDA published its first edition of the 'Purple Book', the biosimilar version of the Agency's Orange Book. The Purple Book actually contains two lists that cross-reference the names of biological products licensed under section 315(a) of the Public Health Service (PHS) Act with the names of biosimilar or interchangeable biological products licensed under section 351(k) of the PHS Act. The two lists cover biological products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research...

The United States Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United States Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the American pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for United States to test other views - a key input for successful budgeting and strategic business planning in the American pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- United Kingdom Pharmaceuticals & Healthcare Report Q1 2015
- Germany Pharmaceuticals & Healthcare Report Q1 2015
- Canada Pharmaceuticals & Healthcare Report Q1 2015
- Jordan Pharmaceuticals & Healthcare Report Q1 2015
- Switzerland Pharmaceuticals & Healthcare Report Q1 2015